today announced that the Company will be presenting on its advanced
computational platform, which integrates physics-based molecular
simulation and machine learning to accelerate drug discovery, at the
upcoming conferences in May:
NewYorkBio in New York City; CEO Ramy Farid will present at the
first New York Emerging Biotech Company Showcase at the New York Stock
Exchange on Monday, May 13 at 2 p.m. ET.
NewYorkBio in New York City; Chief Biomedical Scientist Karen
Akinsanya will join fellow pharma and biotech drug development leaders
on a panel to discuss how data science and artificial intelligence are
shaping the biopharma industry’s therapeutic pipeline at NewYorkBio’s
Annual Meeting on Tuesday, May 14 at 11 a.m. ET.
Bank of America Merrill Lynch Healthcare Conference in Las
Vegas; Senior Vice President Robert Abel will participate in a panel
discussion entitled “How is AI changing the drug discovery paradigm?”
on Tuesday, May 14at 1 p.m. PT and will present on
Thursday, May 16 at 10 a.m. PT.
UBS Global Healthcare Conference in New York City; CEO Ramy
Farid will present on Tuesday, May 21 at 11 a.m. ET.
Schrödinger has a substantial and growing
global business, licensing its industry-leading computational platform
to pharmaceutical, biotechnology, chemical, and electronics companies to
accelerate R&D in both drug discovery and materials design. Schrödinger
has built a robust pipeline of therapeutic assets, held both internally
and in partnerships, and has co-founded leading biotech companies,
including Nimbus Therapeutics and Morphic Therapeutic. Schrödinger’s
significant and ongoing investment in basic research continues to drive
advances in its computational platform. Founded in 1990, Schrödinger has
nearly 400 employees in its New York City headquarters and around the
world. Visit schrodinger.com
for more information.